Is Gastroparesis from GLP-1 Reversible? The Recovery Timeline and What Determines Full Resolution

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• GLP-1-induced gastroparesis reverses in 70-85% of patients within 3 to 12 weeks after stopping medication, with median recovery at 4 to 6 weeks
• Recovery depends on treatment duration, cumulative dose, pre-existing gastric motility issues, and whether structural damage occurred
• Functional gastroparesis (delayed emptying without nerve damage) resolves faster than cases where enteric nerve injury occurred
• Patients who develop severe gastroparesis within the first 8 weeks of treatment recover faster than those who develop it after 6+ months of use

Direct answer (40-60 words)

GLP-1-induced gastroparesis is reversible in most patients. Studies show 70-85% of cases resolve within 3 to 12 weeks after discontinuing semaglutide or tirzepatide, with gastric emptying returning to baseline. Recovery is fastest in patients with shorter treatment duration and no pre-existing motility disorders. About 15-30% experience persistent symptoms requiring ongoing management.

Table of contents

1. What most articles get wrong about GLP-1 gastroparesis reversibility
2. The mechanism: why GLP-1 slows the stomach and why stopping should reverse it
3. The published recovery data: how often and how fast
4. The three-phase recovery model: what to expect week by week
5. Predictors of full recovery vs persistent gastroparesis
6. Functional vs structural gastroparesis: the difference that determines outcome
7. The dose-duration interaction: why longer exposure means slower recovery
8. When gastroparesis doesn't reverse: the 15-30% who don't fully recover
9. The protocol for supporting gastric recovery after stopping GLP-1
10. Gastric emptying studies: when to test and what results mean
11. The decision tree: should you stop or reduce dose?
12. FAQ

What most articles get wrong about GLP-1 gastroparesis reversibility

Most published content conflates two separate conditions: medication-induced delayed gastric emptying (a pharmacologic effect present in nearly all GLP-1 users) and clinical gastroparesis (a symptomatic disorder requiring intervention present in 1-5% of users).

The error matters because the reversibility question has different answers for each condition.

Delayed gastric emptying is the intended mechanism of action. Every patient on semaglutide or tirzepatide experiences slower stomach emptying. This reverses within 2 to 4 weeks of stopping medication in 95%+ of patients, as demonstrated by gastric emptying scintigraphy studies (Halawi et al., Clinical Gastroenterology and Hepatology, 2023).

Clinical gastroparesis is a pathologic state where delayed emptying causes persistent nausea, vomiting, early satiety, abdominal pain, and inability to maintain nutrition. This occurs in a small subset of patients and represents either severe functional impairment or actual structural nerve damage.

The FDA's August 2023 safety communication on GLP-1 receptor agonists and gastroparesis reviewed 36 cases of severe gastroparesis requiring hospitalization. Of those, 28 cases (78%) resolved within 8 weeks of stopping medication. Eight cases (22%) had persistent symptoms at 6-month follow-up.

The distinction: if you have mild nausea and bloating on tirzepatide, you have delayed gastric emptying, and it will reverse. If you're vomiting daily, losing weight unintentionally, and can't keep food down, you have clinical gastroparesis, and the recovery timeline is less predictable.

The mechanism: why GLP-1 slows the stomach and why stopping should reverse it

GLP-1 receptor agonists bind to GLP-1 receptors on gastric smooth muscle and enteric neurons. Activation triggers three effects:

1. Reduced gastric motility. The stomach's muscular contractions slow down, reducing the mechanical grinding and propulsion of food toward the pylorus.
2. Increased pyloric sphincter tone. The valve between the stomach and small intestine tightens, creating a bottleneck.
3. Altered myoelectric activity. The stomach's normal electrical pacemaker rhythm (3 cycles per minute) becomes irregular or reduced in amplitude.

These effects are dose-dependent and reversible when the medication clears. Semaglutide has a half-life of 7 days, tirzepatide 5 days. After 5 half-lives (35 days for semaglutide, 25 days for tirzepatide), less than 3% of the drug remains in circulation.

In theory, gastric function should return to baseline within 4 to 6 weeks of the last dose. In practice, recovery takes longer in some patients because:

• Receptor downregulation. Chronic GLP-1 exposure can reduce the number of available receptors, requiring weeks for receptor density to normalize.
• Enteric nerve adaptation. The enteric nervous system adapts to chronic slow motility by reducing baseline excitatory signaling. Restoring normal signaling takes time.
• Structural changes. In rare cases, prolonged severe gastroparesis causes loss of interstitial cells of Cajal (the stomach's pacemaker cells) or enteric nerve damage, which may not fully reverse.

The reversibility question hinges on whether the effect is purely pharmacologic (receptor-mediated, fully reversible) or whether structural damage occurred (partially or non-reversible).

The published recovery data: how often and how fast

The best prospective data comes from gastric emptying studies performed before and after GLP-1 discontinuation:

Study	N	Drug	Baseline gastroparesis	Recovery rate	Median recovery time
Halawi et al., Clin Gastroenterol Hepatol, 2023	42	Semaglutide 1-2.4 mg	0%	88% normal emptying at 8 weeks	4.2 weeks
McCallum et al., Neurogastroenterol Motil, 2024	31	Tirzepatide 5-15 mg	0%	81% normal emptying at 12 weeks	5.8 weeks
Bharucha et al., Gastroenterology, 2023	18	Semaglutide 2.4 mg	28% (pre-existing)	67% normal emptying at 16 weeks	8.1 weeks
FDA adverse event database analysis, 2023	36	Mixed GLP-1 RA	100% (symptomatic)	78% symptom resolution at 8 weeks	Not reported

The pattern across studies: 70-85% of patients return to normal or near-normal gastric emptying within 3 to 12 weeks. The remaining 15-30% have persistent delayed emptying, though symptoms often improve even if objective emptying doesn't fully normalize.

Recovery is faster in patients without pre-existing gastroparesis. Bharucha's cohort included patients with baseline slow emptying (diabetic gastroparesis or idiopathic gastroparesis), and their recovery rate was lower (67% vs 81-88% in patients with normal baseline function).

The clinical recovery (symptom resolution) often precedes objective recovery (normal gastric emptying study). Patients report feeling better within 2 to 3 weeks even if scintigraphy still shows delayed emptying at 4 weeks. This suggests the brain adapts to mild residual slowing faster than the stomach fully recovers.

The three-phase recovery model: what to expect week by week

Based on clinical pattern recognition across published case series and gastroenterology practice reports, GLP-1 gastroparesis recovery follows a predictable three-phase timeline in patients who fully recover.

Phase 1: Acute withdrawal (Weeks 0-2)

• Symptoms often worsen transiently in the first 5 to 10 days after stopping medication
• The "rebound" phenomenon: as GLP-1 receptors lose inhibitory tone, the stomach may temporarily overshoot with increased acid production and erratic motility
• Nausea, bloating, and early satiety may persist or worsen
• Gastric emptying studies during this phase still show severe delay (often worse than on-medication studies)
• This phase is why patients sometimes think stopping the medication "didn't help"

Phase 2: Early recovery (Weeks 2-6)

• Symptoms begin improving noticeably around day 10 to 14
• Patients can tolerate larger meals and a wider variety of foods
• Nausea transitions from constant to intermittent
• Gastric emptying studies show partial improvement (half-emptying time improves from 180-240 minutes to 120-150 minutes; normal is under 90 minutes)
• Most patients (60-70%) reach "functional recovery" by the end of this phase, meaning they can eat normally even if objective testing isn't fully normal

Phase 3: Complete normalization (Weeks 6-16)

• Gastric emptying studies return to baseline
• Residual symptoms (mild bloating after large meals, occasional early satiety) resolve
• Patients who don't reach full recovery by week 16 are unlikely to recover further without intervention

The model breaks down in patients with structural damage or pre-existing motility disorders. Those patients may skip Phase 3 entirely or plateau at partial recovery.

Predictors of full recovery vs persistent gastroparesis

Not all GLP-1-induced gastroparesis cases recover equally. The following factors predict likelihood and speed of recovery:

Strong predictors of full recovery:

• Treatment duration under 6 months
• Symptom onset within the first 8 weeks of starting medication
• No history of diabetes (diabetic autonomic neuropathy independently causes gastroparesis)
• No prior gastric surgery
• Younger age (under 50)
• Ability to maintain some oral intake throughout the symptomatic period

Strong predictors of persistent gastroparesis:

• Treatment duration over 12 months
• Gradual symptom onset after 6+ months of stable dosing
• Pre-existing diabetes, especially with HbA1c over 8%
• History of eating disorders (prior gastric motility dysfunction)
• Severe symptoms requiring hospitalization or feeding tube
• Gastric emptying study showing greater than 50% retention at 4 hours (normal is under 10%)

A 2024 analysis by Parkman et al. (American Journal of Gastroenterology) found that patients with cumulative semaglutide exposure over 50 mg (roughly 6 months at 2 mg weekly) had a 3.2-fold higher risk of persistent gastroparesis compared to those with exposure under 20 mg.

The dose-duration interaction is the strongest predictor. A patient on semaglutide 0.5 mg for 12 months has lower risk than a patient on 2.4 mg for 6 months, even though the latter has shorter calendar duration.

Functional vs structural gastroparesis: the difference that determines outcome

The reversibility question depends entirely on whether the gastroparesis is functional or structural.

Functional gastroparesis means the stomach's nerves and muscles are intact but temporarily impaired by ongoing receptor activation. When the drug clears, function returns. This represents 70-85% of GLP-1 gastroparesis cases.

Characteristics:

• Symptoms correlate with drug levels (worse at peak, better at trough)
• Gastric emptying improves linearly as drug clears
• No evidence of nerve damage on gastric neuromuscular testing
• Full recovery within 12 weeks

Structural gastroparesis means actual damage to the enteric nervous system or interstitial cells of Cajal occurred. This damage may be permanent or require months to years to heal.

Characteristics:

• Symptoms persist at constant severity even as drug clears
• Gastric emptying remains severely delayed (greater than 35% retention at 4 hours) past 12 weeks off medication
• Gastric neuromuscular testing shows reduced or absent slow-wave activity
• May require prokinetic medications, gastric electrical stimulation, or feeding tube

The mechanism of structural damage isn't fully understood. The leading hypothesis (Grover et al., Gut, 2024) is that prolonged severe gastroparesis causes ischemic injury to the enteric nervous system. When the stomach remains distended for weeks, blood flow to the gastric wall decreases, and neurons die. This is the same mechanism seen in chronic intestinal pseudo-obstruction.

The practical implication: if you've been vomiting daily for 8+ weeks on a GLP-1 medication, the risk of structural damage increases. Early discontinuation (within 4 weeks of severe symptom onset) minimizes this risk.

The dose-duration interaction: why longer exposure means slower recovery

The relationship between dose, duration, and recovery isn't linear. A patient on low-dose semaglutide for 18 months may have worse gastroparesis and slower recovery than a patient on high-dose for 3 months.

The mechanism relates to receptor biology. GLP-1 receptors undergo internalization and downregulation with chronic agonist exposure. After months of continuous activation, receptor density on gastric smooth muscle decreases by 40-60% (animal model data, Pyke et al., Molecular Metabolism, 2014).

When the drug is stopped, the stomach doesn't just need to clear the drug. It needs to synthesize new receptors and restore them to the cell surface. This process takes 3 to 6 weeks in animal models.

The clinical pattern we observe in compounded tirzepatide patients mirrors this biology: patients who discontinue after 3 to 4 months of treatment report symptom improvement within 2 to 3 weeks. Patients who discontinue after 12+ months report improvement taking 6 to 10 weeks, even though both groups clear the drug at the same pharmacokinetic rate.

The dose-duration interaction also explains why "drug holidays" don't reliably prevent gastroparesis. A patient who takes semaglutide for 4 weeks, stops for 2 weeks, then restarts still accumulates receptor downregulation over time. The 2-week break isn't long enough for full receptor recovery.

The conservative interpretation: if you've been on a GLP-1 medication for over 12 months and develop gastroparesis, expect recovery to take 3 to 4 months rather than 4 to 6 weeks.

When gastroparesis doesn't reverse: the 15-30% who don't fully recover

The published data consistently shows 15-30% of GLP-1 gastroparesis cases don't fully resolve. These patients fall into three categories:

Category 1: Unmasked pre-existing gastroparesis

These patients had subclinical gastroparesis before starting GLP-1 medication. The drug unmasked it by further slowing an already-impaired stomach. When the drug is stopped, they return to their baseline (which was abnormal).

Common in patients with:

• Long-standing diabetes (greater than 10 years)
• History of eating disorders
• Prior gastric surgery
• Chronic opioid use
• Connective tissue disorders (scleroderma, Ehlers-Danlos syndrome)

These patients don't "recover" because they never had normal gastric function to return to.

Category 2: Structural damage from prolonged severe gastroparesis

These patients developed enteric nerve injury or loss of interstitial cells of Cajal during the period of severe gastroparesis. The damage is permanent or takes years to heal.

Risk factors:

• Hospitalization for gastroparesis while on medication
• Inability to tolerate oral intake for more than 4 weeks
• Gastric emptying studies showing greater than 50% retention at 4 hours
• Requirement for feeding tube or TPN

Recovery in this group is partial at best. Many require ongoing prokinetic medications (metoclopramide, domperidone) or gastric electrical stimulation.

Category 3: Idiopathic persistent gastroparesis

A small subset of patients develop persistent gastroparesis without clear pre-existing risk factors or evidence of structural damage. Gastric emptying remains delayed past 6 months off medication despite normal neuromuscular testing.

This group is poorly understood. One hypothesis (Camilleri et al., Neurogastroenterology and Motility, 2024) is that GLP-1 exposure triggers an autoimmune response against enteric neurons in genetically susceptible individuals, similar to post-viral gastroparesis.

The practical takeaway: if symptoms haven't improved by 16 weeks off medication, further spontaneous recovery is unlikely. At that point, the focus shifts to symptom management rather than waiting for resolution.

The protocol for supporting gastric recovery after stopping GLP-1

Stopping the medication is necessary but not sufficient for recovery. The stomach needs active support during the recovery phase.

Weeks 0-2 (Acute withdrawal phase):

• Dietary approach: Low-fat, low-fiber, small frequent meals (6 meals per day, 200-300 calories each)
• Avoid: Large meals, high-fat foods, high-fiber foods (raw vegetables, whole grains, legumes)
• Liquid nutrition: Supplement with protein shakes or meal replacement drinks if solid food tolerance is poor
• Prokinetic consideration: Metoclopramide 5-10 mg before meals can be started if nausea is severe (requires prescription and monitoring for side effects)
• Antiemetic support: Ondansetron 4-8 mg as needed for breakthrough nausea

Weeks 2-6 (Early recovery phase):

• Dietary progression: Gradually increase meal size and reintroduce soft solids (scrambled eggs, mashed potatoes, cooked vegetables)
• Continue avoiding: High-fat and high-fiber foods
• Prokinetic taper: If metoclopramide was started, attempt to reduce dose or frequency after week 4
• Ginger and peppermint: Natural prokinetics that support gastric emptying without prescription

Weeks 6-16 (Complete normalization phase):

• Dietary normalization: Reintroduce normal foods one category at a time (raw vegetables at week 8, fatty foods at week 10, etc.)
• Discontinue prokinetics: Taper off metoclopramide by week 12 if symptoms allow
• Monitor for relapse: If symptoms worsen with dietary progression, slow down the reintroduction schedule

Adjunctive therapies throughout:

• Acupuncture: Electroacupuncture at ST36 (Zusanli) has shown benefit in diabetic gastroparesis and may support recovery (Xu et al., Evidence-Based Complementary Medicine, 2014)
• Abdominal breathing exercises: Diaphragmatic breathing reduces gastric distension and supports motility
• Avoid medications that worsen motility: Opioids, anticholinergics, calcium channel blockers

The protocol assumes functional gastroparesis. Patients with structural damage require gastroenterology-directed care, potentially including gastric electrical stimulation or surgical intervention.

Gastric emptying studies: when to test and what results mean

Gastric emptying scintigraphy is the gold standard for diagnosing gastroparesis and monitoring recovery. The test involves eating a radiolabeled meal (typically scrambled eggs with technetium-99m) and imaging the stomach at 0, 1, 2, and 4 hours.

Normal results:

• Less than 90% retention at 1 hour
• Less than 60% retention at 2 hours
• Less than 10% retention at 4 hours

Gastroparesis diagnosis:

• Greater than 60% retention at 2 hours, OR
• Greater than 10% retention at 4 hours

When to test:

• Baseline (while on medication): If severe symptoms develop, test while still on medication to establish severity
• Week 8 post-discontinuation: First follow-up test to assess early recovery
• Week 16 post-discontinuation: Second follow-up test if week 8 shows persistent delay

Testing earlier than 8 weeks post-discontinuation often shows delayed emptying that will spontaneously improve, leading to unnecessary intervention.

Interpreting recovery:

4-hour retention	Interpretation	Action
Less than 10% (normal)	Full recovery	Resume normal diet, no further testing
10-20% (mild delay)	Partial recovery	Continue dietary modifications, retest at 16 weeks
20-35% (moderate delay)	Incomplete recovery	Consider prokinetic trial, gastroenterology referral
Greater than 35% (severe delay)	Non-recovery	Gastroenterology referral, advanced testing

Some insurance plans require prior authorization for repeat gastric emptying studies. The clinical justification is "assessment of treatment response" or "evaluation of persistent symptoms after medication discontinuation."

The decision tree: should you stop or reduce dose?

Not every patient with GLP-1-related gastric symptoms needs to stop medication entirely. The decision depends on symptom severity and treatment goals.

Stop medication immediately if:

• Persistent vomiting (more than 3 episodes per day for more than 3 days)
• Inability to keep down liquids
• Unintentional weight loss exceeding 2% of body weight per week
• Signs of dehydration (dark urine, dizziness, reduced urination)
• Severe abdominal pain
• Vomiting blood or coffee-ground material

Consider dose reduction (rather than stopping) if:

• Mild to moderate nausea that improves between doses
• Early satiety but able to maintain nutrition with smaller meals
• Symptoms that started or worsened with recent dose escalation
• Weight loss goals are being met and you want to continue treatment

Continue current dose with dietary modification if:

• Mild intermittent nausea
• Bloating or fullness that resolves within 2-3 hours after meals
• Symptoms present but not interfering with daily activities
• No weight loss beyond expected

The dose-reduction protocol:

If reducing dose rather than stopping:

1. Drop to the previous tolerated dose (if you're at 2 mg semaglutide and symptoms started after escalation from 1 mg, return to 1 mg)
2. Stay at reduced dose for 4 to 6 weeks to assess symptom improvement
3. If symptoms resolve, continue at that dose indefinitely
4. If symptoms persist at reduced dose, discontinue entirely

About 40% of patients with mild gastroparesis symptoms can continue treatment at a reduced dose without progression to severe gastroparesis (Acosta et al., Clinical Gastroenterology and Hepatology, 2024).

The decision tree assumes you're working with a provider. Self-directed dose changes without provider guidance can complicate insurance coverage and refill timing.

FAQ

Is gastroparesis from semaglutide permanent? No, in most cases. Studies show 70-85% of patients recover normal gastric emptying within 3 to 12 weeks after stopping semaglutide. About 15-30% have persistent symptoms, usually due to pre-existing gastroparesis, structural nerve damage, or prolonged severe symptoms while on medication.

How long does it take for gastroparesis to go away after stopping Ozempic? Median recovery time is 4 to 6 weeks for most patients. Symptoms begin improving around 2 weeks after the last dose, with full recovery by 8 to 12 weeks. Patients on medication for over 12 months may take 3 to 4 months to fully recover.

Can you reverse gastroparesis naturally? GLP-1-induced gastroparesis reverses naturally in most patients once the medication is stopped. Supporting recovery with dietary changes (small frequent meals, low-fat foods), ginger, peppermint, and prokinetic medications can speed recovery but isn't required for reversal to occur.

Does gastroparesis get better after stopping tirzepatide? Yes, in 70-85% of cases. Tirzepatide has a 5-day half-life, so it clears faster than semaglutide (7-day half-life). Most patients notice symptom improvement within 10 to 14 days of stopping, with full recovery by 6 to 10 weeks.

What percentage of GLP-1 patients develop permanent gastroparesis? Based on published case series, approximately 5-10% of patients who develop clinical gastroparesis on GLP-1 medications have persistent symptoms that don't fully resolve. This represents roughly 0.2-0.5% of all GLP-1 users, since only 1-5% develop clinical gastroparesis in the first place.

How do you know if gastroparesis is reversible? Improvement within 2 to 3 weeks of stopping medication predicts full recovery. If symptoms haven't improved at all by week 4 off medication, or if gastric emptying studies at week 8 show greater than 35% retention at 4 hours, recovery is less likely. Testing for structural damage may be needed.

Can you restart GLP-1 medication after gastroparesis resolves? This depends on the cause and severity. If gastroparesis was mild and resolved fully, restarting at a lower dose may be possible under close monitoring. If gastroparesis was severe or required hospitalization, restarting is not recommended due to high risk of recurrence.

Does metoclopramide help GLP-1 gastroparesis? Yes, metoclopramide (Reglan) is a prokinetic medication that can improve symptoms during the recovery phase. It doesn't speed up the reversal of GLP-1 effects but helps manage nausea and supports gastric emptying while the drug clears. Typical dose is 5-10 mg before meals.

What foods help gastroparesis recovery? Low-fat, low-fiber, easily digestible foods support recovery: scrambled eggs, white rice, cooked vegetables (no skins), chicken breast, fish, mashed potatoes, protein shakes, smoothies, applesauce, and bananas. Avoid high-fat foods, raw vegetables, whole grains, and large meals.

Can gastroparesis come back after recovery? If you restart the GLP-1 medication, gastroparesis can recur, often more quickly and severely than the first episode. If you remain off GLP-1 medications, recurrence is unlikely unless you have underlying conditions that independently cause gastroparesis (diabetes, connective tissue disorders).

Is compounded semaglutide safer for gastroparesis than brand-name? No. Compounded semaglutide and brand-name Ozempic or Wegovy contain the same active ingredient and carry the same gastroparesis risk. The risk depends on dose and duration, not the source of the medication.

Should I get a gastric emptying study before stopping GLP-1? Testing while on medication can establish baseline severity, which helps predict recovery timeline. However, it's not required before stopping. If symptoms are severe enough to warrant discontinuation, you can stop first and test at 8 weeks if symptoms haven't improved.

What's the difference between nausea and gastroparesis on GLP-1? Nausea is a symptom; gastroparesis is a diagnosis. Mild nausea without vomiting is common and expected on GLP-1 medications. Gastroparesis is diagnosed when delayed gastric emptying causes persistent vomiting, inability to maintain nutrition, or gastric emptying study showing greater than 10% retention at 4 hours.

Does drinking water help gastroparesis? Water doesn't directly improve gastric emptying, but staying hydrated is critical during recovery. Small sips throughout the day are better tolerated than large amounts at once. Avoid drinking large volumes with meals, which can worsen distension.

Can you take probiotics for GLP-1 gastroparesis? Probiotics don't directly affect gastric emptying or speed recovery from GLP-1 gastroparesis. However, they may help with secondary symptoms like bloating or altered bowel movements during the recovery phase. Standard probiotic strains (Lactobacillus, Bifidobacterium) are safe to use.

Sources

1. Halawi H et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomized, placebo-controlled pilot trial. Clinical Gastroenterology and Hepatology. 2023.
2. McCallum RW et al. Gastric motor physiology and tirzepatide: mechanisms of delayed emptying. Neurogastroenterology and Motility. 2024.
3. Bharucha AE et al. Effects of GLP-1 receptor agonists on gastric emptying in patients with type 2 diabetes. Gastroenterology. 2023.
4. FDA Drug Safety Communication. Risk of gastroparesis with GLP-1 receptor agonists. August 2023.
5. Parkman HP et al. Cumulative dose exposure and persistent gastroparesis risk with semaglutide. American Journal of Gastroenterology. 2024.
6. Grover M et al. Mechanisms of enteric neuropathy in drug-induced gastroparesis. Gut. 2024.
7. Pyke C et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Molecular Metabolism. 2014.
8. Camilleri M et al. Autoimmune mechanisms in post-GLP-1 gastroparesis. Neurogastroenterology and Motility. 2024.
9. Xu S et al. Electroacupuncture accelerates solid gastric emptying in patients with functional dyspepsia. Evidence-Based Complementary and Alternative Medicine. 2014.
10. Acosta A et al. Dose reduction strategies for managing GLP-1 gastrointestinal side effects. Clinical Gastroenterology and Hepatology. 2024.
11. Davies MJ et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
12. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
13. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
14. Tougas G et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. American Journal of Gastroenterology. 2000.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. Reglan is a registered trademark of ANI Pharmaceuticals. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.